Sep 24, 2026 05:40AM
Sep 23, 2026 04:01PM
Sep 23, 2026 04:01PM
Sep 18, 2026 09:00AM
Sep 18, 2026 09:00AM
May 7, 2026 04:01PM
Nov 10, 2025 04:01PM Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress
Oct 23, 2025 06:33AM
Oct 22, 2025 07:30AM
Oct 22, 2025 07:30AM
Aug 11, 2025 04:01PM
Jun 30, 2025 11:00AM
Jun 30, 2025 11:00AM
Jun 23, 2025 08:30AM Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
May 12, 2025 04:01PM
Apr 11, 2025 06:37AM
Apr 10, 2025 08:00AM
Apr 10, 2025 08:00AM
Mar 10, 2025 06:44AM
Mar 10, 2025 05:14AM
Mar 6, 2025 04:01PM Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress
Feb 18, 2025 06:47AM
Feb 3, 2025 06:39AM
Jan 6, 2025 04:01PM
Nov 11, 2024 04:01PM
Nov 11, 2024 04:01PM
Nov 7, 2024 04:01PM
Oct 2, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Arcturus Therapeutics (ARCT)
Sep 4, 2024 06:53AM
Sep 3, 2024 08:33AM
Sep 3, 2024 08:30AM
Jul 1, 2024 04:01PM
Jul 1, 2024 04:01PM
Jun 7, 2024 10:32AM
Jun 7, 2024 10:30AM Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
May 28, 2024 06:30AM
May 28, 2024 06:30AM
Mar 7, 2024 04:01PM
Feb 22, 2024 08:31AM
Feb 22, 2024 08:30AM
Nov 27, 2023 08:31AM
Nov 27, 2023 08:30AM Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
Nov 14, 2023 04:01PM
Aug 7, 2023 04:01PM
Jun 1, 2023 08:30AM
Jun 1, 2023 08:30AM
May 12, 2023 08:45AM
Apr 21, 2022 06:14AM
Apr 20, 2022 07:31AM Arcturus Therapeutics (ARCT) Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Apr 20, 2022 07:30AM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All